Abstract
Interleukin-2 (IL-2) is a secretory product of activated T-lymphocytes that has profound effects on the immune response. In particular, IL-2 has been shown to enhance the in vitro tumoricidal activity of peripheral-blood mononuclear cells [1] and to induce the formation of lymphokine-activated killer (LAK) cells which are able to lyse a broad spectrum of malignant cells in vitro [2]. Clinical trials using high doses of recombinant human IL-2, with or without autologous LAK cells, have yielded promising results, particularly in patients with melanoma or renal cell carcinoma [3–8]. This therapy has also been accompanied by multiple acute but generally reversible toxic effects, including fever, chills, lethargy, diarrhea, anemia, thrombocytopenia, eosinophilia, confusion, diffuse erythroderma, hepatic dysfunction, myocarditis and myocardial infarction, defects in neutrophil function, bacterial sepsis, and a capillary leak syndrome leading to hypotension, fluid retention, and renal insufficiency [3,5,8–13].
Supported in part by a General Clinical Research Center Grant (RR-00088) and a Clinical Associate Physician Award to M.B. A. (3-M01 RR-000054–2052) from the Division of Research Resources, National Institutes of Health, and by a contract (N01-CM-73 706) with the National Cancer Institute; a portion of this data was published in the New England Journal of Medicine 318:1556–1563, 1988.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291:335–338
Grimm DA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841
Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl JMed 313:l485–1492
Lotze MT, Chang AE, Scipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patient with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256:3117–124
Rosenberg SA, Lotze MT, Muul IM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897.
Fisher RI, Coltman CA Jr, Doroshow JH et al. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann Intern Med 108:518–523
Dutcher JP, Creekmore S, Weiss GR et al. (1989) Phase II study of interleukin-2 and lym-phokine-activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477–485
Hawkins MJ (1989) IL2/LAK: current status and possible future directions. In: Devita VT, Hellman S, Rosenberg St (eds) Principles and practice of oncology update, 8(3). Lip-pincott, Philadelphia, pp 1–14
Margolin K, Rayner AA, Hawkins M et al. (1989) Interleukin-2 and lymphokine activated killer cell therapy: analysis of toxicity and management guidelines. J Clin Oncol 7:486–498
Mier J, Aronson F, Numerof R, Vachino G, Atkins M (1988) Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. J Pathol Immunopathol Res 7: 459–476
Atkins MB, Gould JA, Allegretta M et al. (1986) Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 4:1380–1391
Klempner M, Noring R, Mier J, Atkins M (1990) An acquired neutrophil chemo tactic defect in patients receiving immunotherapy with interleukin-2. N Engl J Med 322:959–965
Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB (1990) Nosocomial sepsis associated with interleukin-2. Ann Intern Med 112:102–107
Atkins M, Mier J, Parkinson D, Gould J, Berkman EM, Kaplan M (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557–1562
Beever K, Bradbury J, Phillips D et al. (1989) Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 35:1949–1954
Lotze MT, Matory YL, Ettinghausen SE et al. (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865–2875
Mier J, Vachino G, Van der Meer J et al. (1988) Induction of circulating tumor necrosis factor (TNF) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426–436
Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagi K (1983) Natural killer (NK) cells as a responder to interleukin 2 (IL2). II. IL2-induced interferon γproduction. J Immunol 130: 988–992
Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL (1985) Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1:1166
Burman P, Totterman TH, Oberg K, Karlsson FA (1986) Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63:1086–1090
Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Botlazzo GF (1988) An autoimmune etiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24:1299–1303
Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES (1987) The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129:208–216
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223:1318–1321
Rosenberg SA, Packard BS, Aebersold PM et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676–1680
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Atkins, M.B., Kaplan, M.M., Demchak, P.A., Robert, N.J., Reichlin, S., Mier, J.W. (1991). Thyroid Dysfunction After High-Dose Interleukin-2 Therapy: An Update. In: Scherbaum, W.A., Bogner, U., Weinheimer, B., Bottazzo, G.F. (eds) Autoimmune Thyroiditis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76301-4_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-76301-4_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53476-1
Online ISBN: 978-3-642-76301-4
eBook Packages: Springer Book Archive